Seeking Alpha

Marty Chilberg's  Instablog

Marty Chilberg
Send Message
I'm a retired CPA who spent the majority of his working career in technology companies. My work included management stints at Atari Inc, Daisy Systems Corp, Symantec Corp and Visio Corp. My last position at Visio (VSIO) was as CFO and VP Finance and Operations.
View Marty Chilberg's Instablogs on:
  • Carrier Screening Info

    Note Sequenom carrier screen HerediT Cystic Fibrosis did about 33,000 tests in 2013, up about 20% from 2012.

    US Cystic Fibrosis Carrier Screening Market Swells to More than US$ 300 Million

    According to a new research report by RNCOS entitled, "Genetic Testing Market Outlook to 2017", more and more would be American parents are opting for cystic fibrosis (CF) carrier screening test to assess the chances of having a baby suffering with cystic fibrosis. The private sector is actively participating in this robust field attracted by the more than 1 Million CF carrier screening tests that are performed each year in the US. With an average reimbursement rate of US$ 200- 400 per test; the US market is estimated to be in excess of US$ 300 Million per year and witness a high digit growth rate in future.

    Coverage of Carrier Screening

    Tuesday, September 24, 2013

    This message is regarding genetic tests used to determine carrier status for cystic fibrosis (CF), Fragile X, and spinal muscular atrophy (SMA). Consistent with the recommendations set forth by ACMG and ACOG, OHCA considers CF carrier screening using the common mutation panel (CPT code 81220) to be medically necessary once in a lifetime for women of reproductive age and the partners of those that test positive. Expanded mutation panels beyond those recommended by ACMG/ACOG are not considered medically necessary and will be reimbursed at a rate that is based on the common variant panel alone. OHCA does not consider other carrier screening in the general population to be medically necessary. In particular, carrier screening for Fragile X (CPT code 81243) and SMA (CPT code 81401) are not considered medically necessary in the absence of a family history suggestive of those conditions. This is consistent with the ACOG and ACMG recommendations for Fragile X carrier screening and the ACOG recommendations for SMA carrier screening.

    Disclosure: I am long SQNM.

    Apr 18 7:39 PM | Link | Comment!
  • Market Research Report On NIPT

    Market research report should be published next week. Table of Contents preview:

    Market Analysis of Non-Invasive Prenatal Screening

    Summary

    Sizing the Market

    • Overview
    • Birth rate
    • Risk segments
    • Payer profile
    • Market size conclusions

    Focus International Markets

    • Brazil
    • Mexico
    • EU 5
    • China
    • India
    • Japan

    Americas Market

    • North
    • Central
    • Caribbean
    • South

    European Market

    • Northern
    • Western
    • Eastern
    • Southern

    Asian Market

    • Western
    • South Central
    • Southeast
    • East

    Rest of World Market

    • Africa
    • Oceania

    Investing the Space

    • Ariosa Diagnostics, Inc. (AROS)
    • Illumina, Inc. (ILMN)
    • Natera, Inc. (private)
    • Sequenom, Inc. (SQNM)

    NIPT Market Summary

    Disclosure: I am long SQNM.

    Apr 18 1:21 PM | Link | Comment!
  • Ariosa Amended S-1: Roadshow Next

    Ariosa (AROS) amended their Form S-1 to include Q1-2014 results. A few highlights included in new filing:

    Q1-14 revenues $19.5 vs $9.6 PY

    • ASP $377 vs $380
    • International $6.9m vs $0.6m
    • Domestic $12.6m vs 9.0m
    • Tests 51,700 vs 25,200
    • LabCorp $12.1m vs $9.0m

    Q1-14 net income of $1.1m

    Cash increased sequentially to $16.8m from $14M

    Company included disclosure that they expected to generate losses after this quarter. Likely due to the incremental spend in SG&A and some disruption from amended LabCorp agreement.

    International revenues of approximately $7m compares with Sequenom reported results in Q4-13 of $3.7m. Clearly appears that internationally Ariosa has a substantial advantage currently.

    Disclosure: I am long SQNM.

    Apr 17 1:04 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.